Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized coaching via smartphone could curb hypertension before it starts

NCT ID NCT07804420

Prevention Sponsor: Peking University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This trial tests whether a personalized health program delivered through a WeChat mini-program and community health workers can lower blood pressure in adults at high risk of developing hypertension. Researchers will enroll 500 adults aged 35 to 65 in Beijing who have a predicted hypertension risk above 20% but do not yet have the condition. Participants in the intervention group receive tailored education, behavioral goal setting, and tools like salt-restriction spoons, while the control group gets standard health education. The main goal is to see if the program reduces systolic and diastolic blood pressure compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A personalized health management program delivered through a WeChat mini-program and community healthcare providers, including health education, behavioral goal setting, and blood pressure monitoring guidance.
What this could lead to
If successful, this approach could offer a scalable, low-cost way to prevent hypertension in high-risk adults, potentially reducing future heart disease and stroke.
What could go wrong
The trial is relatively small and community-based, so results may not apply broadly. Success depends on participants sticking with the program, and blood pressure changes may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Aged 35 to 65 years. Permanent resident of Shunyi District, Beijing, China. Identified as being at high risk of developing hypertension through the Hypertension Risk Assessment WeChat mini-program, with a predicted hypertension risk greater than 20%. No current diagnosis of hypertension, with systolic blood pressure \<140 mmHg and diastolic blood pressure \<90 mmHg, and not currently taking antihypertensive medication. Willing to participate in the study and able to provide written informed consent. Owns a smartphone and is able to use basic WeChat functions. Exclusion Criteria: Previously diagnosed hypertension or current use of antihypertensive medications. History of serious cardiovascular or cerebrovascular disease, such as myocardial infarction or stroke. Severe hepatic or renal dysfunction, malignant tumor, serious psychiatric disorder, or other serious disease. Planning to move out of Shunyi District within the next 9 months. Currently participating in another similar intervention study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • Shunyi District Center for Disease Control and Prevention, Beijing

    Beijing, Beijing Municipality, 101300, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.